Kisspeptin: The Peptide That Triggers Ovulation Without Hyperstimulation

The Problem Kisspeptin Solves

In vitro fertilization requires a trigger — a hormonal signal that tells the ovaries to complete final egg maturation so the eggs can be retrieved. For decades, that trigger has been human chorionic gonadotropin (hCG). It works. But it carries a serious risk.

Ovarian hyperstimulation syndrome (OHSS) occurs when the ovaries over-respond to hCG, swelling dramatically and leaking fluid into the abdomen and chest. Mild OHSS is uncomfortable. Severe OHSS is a medical emergency that can cause blood clots, kidney failure, respiratory distress, and in rare cases death. It affects 1–5% of IVF cycles, but the rate climbs much higher in women who are at greatest risk — those with PMOS (formerly PCOS), who tend to develop many follicles that respond aggressively to stimulation.

This is the problem kisspeptin may solve.

What Kisspeptin Actually Is

Kisspeptin is not a drug designed in a lab. It is a naturally occurring peptide hormone, encoded by the KISS1 gene, that your hypothalamus produces every menstrual cycle. It is the master upstream switch for the entire HPG (hypothalamic-pituitary-gonadal) axis — the hormonal cascade that governs ovulation, menstruation, puberty, and fertility.

In a normal cycle, kisspeptin neurons in the hypothalamus signal GnRH (gonadotropin-releasing hormone) neurons to fire. GnRH triggers the pituitary gland to release a surge of LH (luteinizing hormone). That LH surge tells the ovary to release a mature egg. This is ovulation.

When this cascade breaks — as it does in PMOS, hypothalamic amenorrhea, and other forms of anovulation — ovulation doesn't happen. The conventional fix is to bypass the broken system entirely with exogenous hormones (Clomid, letrozole, gonadotropins, hCG). Kisspeptin's potential is that it works with the system rather than around it, triggering a physiological LH surge that's shorter-lived and more controllable than hCG's prolonged ovarian stimulation.

The Dhillo Group's Research

The most important body of kisspeptin fertility research comes from Professor Waljit Dhillo's lab at Imperial College London. Over more than a decade, this group has systematically investigated kisspeptin-54 (the full-length form) as an alternative IVF trigger.

The Core Finding

In multiple clinical studies, kisspeptin-54 administered as a single subcutaneous injection successfully triggered final oocyte maturation in women undergoing IVF — producing viable eggs for retrieval — without a single case of clinically significant OHSS, even in high-risk patients.

Why the difference? The mechanism matters. hCG binds directly to LH receptors on the ovary and keeps stimulating them for days (its half-life is roughly 24–36 hours). This prolonged stimulation is what drives the vascular permeability and fluid shifts behind OHSS. Kisspeptin triggers a natural LH surge from the pituitary — a surge that peaks and falls within hours, as it does in a normal menstrual cycle. The signal is strong enough to mature eggs, short enough to avoid hyperstimulation.

The PMOS Connection

The Dhillo group has specifically studied kisspeptin in women with PMOS — the population at highest OHSS risk. In a 2024 randomized controlled trial, kisspeptin triggered successful oocyte maturation in women with PMOS undergoing IVF, with pregnancy rates comparable to standard protocols and no OHSS events.

This is significant because PMOS-related infertility involves disrupted kisspeptin signaling at a fundamental level. Women with PMOS often have abnormal kisspeptin neuron activity — the upstream switch that's supposed to coordinate the LH surge is misfiring. Exogenous kisspeptin doesn't fix that misfiring, but it does provide the specific signal the downstream system needs to complete ovulation.

Beyond IVF: Kisspeptin as a Hormonal Hub

The fertility application is the most clinically advanced, but kisspeptin's role in the body extends well beyond triggering ovulation.

A 2026 review by Xu et al. in Comprehensive Physiology describes kisspeptin neurons as an "integrative hub" connecting three major endocrine axes during perimenopause:

• The HPG axis (reproductive hormones) — kisspeptin's primary role in ovulation and menstrual regulation.
• The HPT axis (thyroid function) — kisspeptin neurons interact with thyroid-regulating pathways, potentially contributing to the thyroid dysfunction that frequently accompanies PMOS and perimenopause.
• The HPA axis (stress response) — kisspeptin signaling is sensitive to metabolic stress, which helps explain why extreme dieting, overexercise, and chronic stress can shut down ovulation (functional hypothalamic amenorrhea).

What Kisspeptin Can't Do (Yet)

Honesty about limitations matters more than hype, especially with fertility:

• It is not FDA-approved. Kisspeptin is not available through any fertility clinic, pharmacy, or telehealth provider as a clinical treatment. It is still in clinical trials.
• Research-grade kisspeptin-10 is not the same. The clinical research uses kisspeptin-54 (the full-length peptide). Research-vendor kisspeptin-10 is a truncated fragment with different pharmacokinetics. The IVF trigger data comes from kisspeptin-54 specifically.
• It doesn't fix the underlying cause of anovulation. Kisspeptin provides the missing signal to trigger ovulation; it doesn't repair the metabolic dysfunction (insulin resistance, androgen excess) that disrupts ovulation in PMOS. Addressing root causes still matters.
• Pregnancy rates need larger trials. The studies so far are relatively small. Kisspeptin triggers oocyte maturation effectively and avoids OHSS, but demonstrating equivalent (or superior) pregnancy rates compared to standard protocols requires larger Phase 3 trials.

The Research You Haven't Heard About

Beyond fertility, kisspeptin research has produced several findings that are rarely discussed outside specialized endocrinology journals:

Kisspeptin and sexual arousal. The Dhillo group published neuroimaging data showing that kisspeptin administration enhances brain activity in regions associated with sexual arousal and attraction. In men and women, kisspeptin increased limbic and paralimbic brain activation in response to sexual stimuli. This opens a theoretical connection between kisspeptin and hypoactive sexual desire — a condition that currently has only one FDA-approved treatment for premenopausal women (PT-141/Vyleesi).

Kisspeptin and mood. The same neuroimaging work showed that kisspeptin modulated activity in brain regions associated with negative mood states, suggesting potential antidepressant-like effects. This is early-stage, but intriguing given the well-documented relationship between reproductive hormones and mood disorders in women.

Kisspeptin and metabolic health. Kisspeptin receptors are expressed in the pancreas and adipose tissue. Emerging research suggests kisspeptin may directly influence insulin secretion and glucose metabolism — independent of its reproductive role. For women with PMOS, where insulin resistance is both cause and consequence, this metabolic dimension adds another layer of potential relevance.

Where This Is Heading

The most likely near-term clinical application is kisspeptin as an alternative IVF trigger for high-risk women — particularly those with PMOS. If ongoing Phase 2 and Phase 3 trials confirm the safety and efficacy signal, this could become standard of care for the subset of IVF patients who currently face the highest OHSS risk.

Broader applications — kisspeptin for anovulatory infertility outside IVF, for hypothalamic amenorrhea, or for sexual desire — are further out and less certain. The integrative-hub concept is compelling biology, but biology and approved therapeutics are different timelines.

For women with PMOS who are navigating fertility, the practical takeaway is this: kisspeptin represents one of the most promising peptide-based fertility developments in a decade, and it directly addresses the condition that makes IVF most dangerous for you. It is not available yet. Track the Dhillo group's publications and the pipeline of kisspeptin clinical trials. When it arrives, it could change the risk calculation of IVF substantially.